Current treatment guidelines refer to small cell lung cancer (SCLC), one of the deadliest
human malignancies, as a homogeneous disease. Accordingly, SCLC therapy comprises …

Simple Summary Despite recent advances in targeted therapy and immunotherapy, the
treatment of lung cancer remains challenging due to its high metastatic potential, which …

Current management of small cell lung cancer (SCLC) remains challenging. Effective
biomarkers are needed to subdivide patients presenting distinct treatment response and …

Lung cancer is the common malignant tumor with the highest mortality rate. Lung cancer
patients have achieved benefits from immunotherapy, including immune checkpoint …

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that lacks
estrogen and progesterone receptors and does not overexpress the human epidermal …

Lung cancer still is one of the most common malignancy tumors in the world. However, the
mechanisms of its occurrence and development have not been fully elucidated. Zinc finger …

Background Small cell lung cancer (SCLC) is a highly aggressive disease characterized by
early metastasis. Aneuploid CD31-disseminated tumor cells (DTCs) and CD31+ …

Background Patients with extensive‐stage small cell lung cancer (ES‐SCLC) have an
exceptionally poor prognosis and immune checkpoint inhibitors (ICIs) combined with …

There is currently scarcity of information on small cell neuroendocrine carcinoma of the
nasopharynx (SCNEC-nasopharynx). It is believed that this type of cancer is not associated …

Precision medicine has revolutionized lung cancer management–particularly non-
squamous cell carcinomas–with a broader genomic comprehension and the possibility of …